Drug intelligence / Profile preview

Rsol-DSR Capsule

Development stage: Unknown
Lead developer: Solvix Pharma
Modality: Small Molecules
Administration: Oral

Overview

Rsol-DSR Capsule is a combination pharmaceutical drug used to treat symptoms of acid reflux, stomach ulcers, peptic ulcer disease, Zollinger-Ellison syndrome, gastroesophageal reflux disease (GERD), duodenal ulcers, gastric ulcers, and Crohn's disease-associated ulcers. It contains two active ingredients: Rabeprazole, a proton pump inhibitor that reduces stomach acid production by blocking the H+/K+ ATPase enzyme, and Domperidone, a dopamine D2 receptor antagonist that increases the motility of the upper gastrointestinal tract and blocks the chemoreceptor trigger zone (CTZ) to prevent vomiting. The drug is manufactured by Solvix Pharma.

Brand names: Rsol-DSR Capsule

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on Rsol-DSR Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rsol-DSR Capsule.

Explore the full profile